Setting

Asia Pacific Point of Care (PoC) Molecular Diagnostics Market 2020-2030 by Product (Assays, Instruments, Software), Technology (PCR, INAAT, Microarray), Application, End User, and Country: Trend Forecast and Growth Opportunity

Published: 28 Sep 2020 | Report Code: 10247708 | Pages: 124

Asia Pacific PoC molecular diagnostics market will grow by 15.1% annually with a total addressable market cap of $8,360.1 million over 2020-2030 owing to the rising adoption of PoC molecular diagnostics for drug discovery and development amid COVID-19 pandemic. Highlighted with 34 tables and 52 figures, this 124-page report “Asia Pacific Point of Care (PoC) Molecular Diagnostics Market 2020-2030 by Product (Assays, Instruments, Software), Technology (PCR, INAAT, Microarray), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific PoC molecular diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific PoC molecular diagnostics market in every aspect of the classification from perspectives of Product, Technology, Application, End User, and Country. Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Kits & Assays • Analyzers & Instruments • Software & Services Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Polymerase Chain Reaction (PCR) • Real-Time PCR (rt-PCR) • Digital PCR (d-PCR) Isothermal Nucleic Acid Amplification Technology (INAAT) Genetic Sequencing-based Technology Microarray-based Technology Other Technologies Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Infectious Disease • Respiratory Infections • Hospital Acquired Infections • Sexually Transmitted Infections Gastrointestinal Infections Oncology Hepatitis Prenatal/Neonatal Testing Other Applications Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Hospitals • Clinics & Diagnostic Centers • Research and Academic Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) Detailed analysis and 2019-2030 annual revenue are available for each key national market. The breakdown of key national markets by Product, Technology, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific PoC molecular diagnostics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abacus Diagnostica Oy Abbott Laboratories Alere Inc. Biocartis Group NV Biomerieux SA Bio-Rad Laboratories Inc Danaher Corporation DiaSorin S.p.A DxNA LLC. F. Hoffmann-La Roche Ltd. Hologic, Inc. Luminex Corporation Meridian Bioscience Inc. Mesa Biotech Inc. QIAGEN N.V. QuantuMDx Group Ltd. Quidel Corporation Spartan Biosciences Inc. Thermo Fisher Scientific (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	24
2.2 Major Growth Drivers	26
2.3 Market Restraints and Challenges	31
2.4 Emerging Opportunities and Market Trends	34
2.5 Porter’s Fiver Forces Analysis	38
3 Segmentation of Asia Pacific Market by Product	43
3.1 Market Overview by Product	43
3.2 Kits & Assays	45
3.3 Analyzers & Instruments	46
3.4 Software & Services	47
4 Segmentation of Asia Pacific Market by Technology	48
4.1 Market Overview by Technology	48
4.2 Polymerase Chain Reaction (PCR)	50
4.2.1 Real-Time PCR (rt-PCR)	51
4.2.2 Digital PCR (d-PCR)	52
4.3 Isothermal Nucleic Acid Amplification Technology (INAAT)	53
4.4 Genetic Sequencing-based Technology	54
4.5 Microarray-based Technology	55
4.6 Other Technologies	56
5 Segmentation of Asia Pacific Market by Application	57
5.1 Market Overview by Application	57
5.2 Infectious Disease	59
5.2.1 Respiratory Infections	61
5.2.2 Hospital Acquired Infections	62
5.2.3 Sexually Transmitted Infections	63
5.3 Gastrointestinal Infections	64
5.4 Oncology	65
5.5 Hepatitis	66
5.6 Prenatal/Neonatal Testing	67
5.7 Other Applications	68
6 Segmentation of Asia Pacific Market by End User	69
6.1 Market Overview by End User	69
6.2 Hospitals	71
6.3 Clinics & Diagnostic Centers	72
6.4 Research and Academic Institutes	73
6.5 Other End Users	74
7 Asia-Pacific Market 2019-2030 by Country	76
7.1 Overview of Asia-Pacific Market	76
7.2 Japan	79
7.3 China	82
7.4 Australia	85
7.5 India	87
7.6 South Korea	89
7.7 Rest of APAC Region	91
8 Competitive Landscape	93
8.1 Overview of Key Vendors	93
8.2 New Product Launch, Partnership, Investment, and M&A	97
8.3 Company Profiles	98
Abacus Diagnostica Oy	98
Abbott Laboratories	100
Alere Inc.	101
Biocartis Group NV	102
Biomerieux SA	103
Bio-Rad Laboratories Inc	104
Danaher Corporation	105
DiaSorin S.p.A	106
DxNA LLC.	107
F. Hoffmann-La Roche Ltd.	108
Hologic, Inc.	109
Luminex Corporation	110
Meridian Bioscience Inc.	111
Mesa Biotech Inc.	112
QIAGEN N.V.	113
QuantuMDx Group Ltd.	114
Quidel Corporation	115
Spartan Biosciences Inc.	116
Thermo Fisher Scientific	117
9 Investing in Asia Pacific Market: Risk Assessment and Management	118
9.1 Risk Evaluation of Asia Pacific Market	118
9.2 Critical Success Factors (CSFs)	121
Related Reports and Products	124
List Of Tables

Table 1.  Snapshot of Asia Pacific Point of Care (PoC) Molecular Diagnostics Market, 2019-2030	18
Table 2. Growth Rate of World Real GDP, 2017-2021	22
Table 3.  Main Product Trends and Market Opportunities in Asia Pacific Point of Care (PoC) Molecular Diagnostics Market	34
Table 4. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market by Product, 2019-2030, $ mn	43
Table 5. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market by Technology, 2019-2030, $ mn	48
Table 6. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Polymerase Chain Reaction (PCR) by Type, 2019-2030, $ mn	50
Table 7. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market by Application, 2019-2030, $ mn	57
Table 8. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Infectious Disease by Type, 2019-2030, $ mn	60
Table 9. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market by End User, 2019-2030, $ mn	69
Table 10. APAC Point of Care (PoC) Molecular Diagnostics Market by Country, 2019-2030, $ mn	77
Table 11. Japan Point of Care (PoC) Molecular Diagnostics Market by Product, 2019-2030, $ mn	81
Table 12. Japan Point of Care (PoC) Molecular Diagnostics Market by Technology, 2019-2030, $ mn	81
Table 13. Japan Point of Care (PoC) Molecular Diagnostics Market by Application, 2019-2030, $ mn	81
Table 14. China Point of Care (PoC) Molecular Diagnostics Market by Product, 2019-2030, $ mn	84
Table 15. China Point of Care (PoC) Molecular Diagnostics Market by Technology, 2019-2030, $ mn	84
Table 16. China Point of Care (PoC) Molecular Diagnostics Market by Application, 2019-2030, $ mn	84
Table 17. Australia Point of Care (PoC) Molecular Diagnostics Market by Product, 2019-2030, $ mn	86
Table 18. Australia Point of Care (PoC) Molecular Diagnostics Market by Technology, 2019-2030, $ mn	86
Table 19. Australia Point of Care (PoC) Molecular Diagnostics Market by Application, 2019-2030, $ mn	86
Table 20. India Point of Care (PoC) Molecular Diagnostics Market by Product, 2019-2030, $ mn	88
Table 21. India Point of Care (PoC) Molecular Diagnostics Market by Technology, 2019-2030, $ mn	88
Table 22. India Point of Care (PoC) Molecular Diagnostics Market by Application, 2019-2030, $ mn	88
Table 23. South Korea Point of Care (PoC) Molecular Diagnostics Market by Product, 2019-2030, $ mn	90
Table 24. South Korea Point of Care (PoC) Molecular Diagnostics Market by Technology, 2019-2030, $ mn	90
Table 25. South Korea Point of Care (PoC) Molecular Diagnostics Market by Application, 2019-2030, $ mn	90
Table 26. Point of Care (PoC) Molecular Diagnostics Market in Rest of APAC by Country, 2019-2030, $ mn	92
Table 27. Breakdown of Asia Pacific Market by Key Vendor, 2019, %	95
Table 28. Abacus Diagnostica Oy: Company Snapshot	98
Table 29. Abacus Diagnostica Oy: Business Segmentation	98
Table 30. Abacus Diagnostica Oy: Product Portfolio	99
Table 31. Abacus Diagnostica Oy: Revenue, 2016-2018, $ mn	99
Table 32. Abacus Diagnostica Oy: Recent Developments	99
Table 33.  Risk Evaluation for Investing in Asia Pacific Market, 2019-2030	119
Table 34. Critical Success Factors and Key Takeaways	122

List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market, 2019-2030, $ mn	20
Figure 6. Impact of COVID-19 on Business	24
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Point of Care (PoC) Molecular Diagnostics Market	26
Figure 8. World Number of Deaths by Cause in 2017	29
Figure 9. World Number of Deaths from Cancers in 2017	30
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Point of Care (PoC) Molecular Diagnostics Market	31
Figure 11. Investment Opportunity Analysis	35
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Point of Care (PoC) Molecular Diagnostics Market	38
Figure 13. Breakdown of Asia Pacific Point of Care (PoC) Molecular Diagnostics Market by Product, 2019-2030, % of Revenue	43
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Product, Value ($ mn) and Share (%)	44
Figure 15. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Kits & Assays, 2019-2030, $ mn	45
Figure 16. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Analyzers & Instruments, 2019-2030, $ mn	46
Figure 17. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Software & Services, 2019-2030, $ mn	47
Figure 18. Breakdown of Asia Pacific Point of Care (PoC) Molecular Diagnostics Market by Technology, 2019-2030, % of Sales Revenue	48
Figure 19. Asia Pacific Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%)	49
Figure 20. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn	50
Figure 21. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Real-Time PCR (rt-PCR), 2019-2030, $ mn	51
Figure 22. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Digital PCR (d-PCR), 2019-2030, $ mn	52
Figure 23. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Isothermal Nucleic Acid Amplification Technology (INAAT), 2019-2030, $ mn	53
Figure 24. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Genetic Sequencing-based Technology, 2019-2030, $ mn	54
Figure 25. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Microarray-based Technology, 2019-2030, $ mn	55
Figure 26. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Other Technologies, 2019-2030, $ mn	56
Figure 27. Breakdown of Asia Pacific Point of Care (PoC) Molecular Diagnostics Market by Application, 2019-2030, % of Sales Revenue	57
Figure 28. Asia Pacific Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)	58
Figure 29. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Infectious Disease, 2019-2030, $ mn	59
Figure 30. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Respiratory Infections, 2019-2030, $ mn	61
Figure 31. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Hospital Acquired Infections, 2019-2030, $ mn	62
Figure 32. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Sexually Transmitted Infections, 2019-2030, $ mn	63
Figure 33. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Gastrointestinal Infections, 2019-2030, $ mn	64
Figure 34. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Oncology, 2019-2030, $ mn	65
Figure 35. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Hepatitis, 2019-2030, $ mn	66
Figure 36. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Prenatal/Neonatal Testing, 2019-2030, $ mn	67
Figure 37. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Other Applications, 2019-2030, $ mn	68
Figure 38. Breakdown of Asia Pacific Point of Care (PoC) Molecular Diagnostics Market by End User, 2019-2030, % of Revenue	69
Figure 39. Asia Pacific Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)	70
Figure 40. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Hospitals, 2019-2030, $ mn	71
Figure 41. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Clinics & Diagnostic Centers, 2019-2030, $ mn	72
Figure 42. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Research and Academic Institutes, 2019-2030, $ mn	73
Figure 43. Asia Pacific Point of Care (PoC) Molecular Diagnostics Market: Other End Users, 2019-2030, $ mn	74
Figure 44. Breakdown of APAC Point of Care (PoC) Molecular Diagnostics Market by Country, 2019 and 2030, % of Revenue	77
Figure 45. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)	78
Figure 46.  Point of Care (PoC) Molecular Diagnostics Market in Japan, 2019-2030, $ mn	80
Figure 47.  Point of Care (PoC) Molecular Diagnostics Market in China, 2019-2030, $ mn	83
Figure 48.  Point of Care (PoC) Molecular Diagnostics Market in Australia, 2019-2030, $ mn	85
Figure 49.  Point of Care (PoC) Molecular Diagnostics Market in India, 2019-2030, $ mn	87
Figure 50.  Point of Care (PoC) Molecular Diagnostics Market in South Korea, 2019-2030, $ mn	89
Figure 51.  Point of Care (PoC) Molecular Diagnostics Market in Rest of APAC, 2019-2030, $ mn	91
Figure 52. Growth Stage of Asia Pacific Point of Care (PoC) Molecular Diagnostics Industry over the Forecast Period	93

Key Players (this may not be a complete list and extra companies can be added upon request): 
Abacus Diagnostica Oy	
Abbott Laboratories	
Alere Inc.	
Biocartis Group NV	
Biomerieux SA	
Bio-Rad Laboratories Inc	
Danaher Corporation	
DiaSorin S.p.A	
DxNA LLC.	
F. Hoffmann-La Roche Ltd.	
Hologic, Inc.	
Luminex Corporation	
Meridian Bioscience Inc.	
Mesa Biotech Inc.	
QIAGEN N.V.	
QuantuMDx Group Ltd.	
Quidel Corporation	
Spartan Biosciences Inc.	
Thermo Fisher Scientific